As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright!

Ventilator-associated pneumonia (VAP) poses a serious threat in ICUs, often driven by biofilms on endotracheal tubes that resist antibiotics. In this Q&A, Professor Frank MP van Haren discusses a study showing that nebulized BromAc® effectively disrupts these biofilms and enhances antibiotic action, offering a promising strategy against persistent infections like Pseudomonas aeruginosa-related VAP.

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

As part of our Future Leaders series, we speak with Dr Helen Gavillet, a post-doctoral researcher at Northumbria University (UK) and Rising Star at RTI 2025. Dr Gavillet's research focuses on the lung microbiome in cystic fibrosis, particularly bacterial and fungal dynamics. Her research also examines the impact of CFTR modulators like elexacaftor/tezacaftor/ivacaftor on respiratory microbiota.

As part of our Future Leaders series, Dr. Shelby MacRae, a pulmonary and critical care specialist at LSUHSC, shares her journey from ICU intern to bronchiectasis and NTM researcher. She discusses challenges in care, lack of awareness, and future advances. Passionate about mentorship, she encourages future pulmonologists to find balance, build foundations, and stay driven by patient needs.

Boehringer Ingelheim has announced that its investigational drug, nerandomilast (BI 1015550), has successfully met the primary endpoint in the phase III FIBRONEER™-ILD study. The trial assessed the absolute change from baseline in forced vital capacity (FVC) [mL] at Week 52 compared ...

A recent single-arm, phase 3 study (RIDGELINE VX21-121-105)1 published in The Lancet Respiratory Medicine2 has shown positive results for vanzacaftor–tezacaftor–deutivacaftor in treating paediatric cystic fibrosis (CF) patients, demonstrating improvements in lung function, sweat chloride levels and quality of life. This trial focused on children aged 6 to 11 years, a group often excluded from studies involving adults or older children, as well as key ages for CF treatment.